查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年奈米医学市场预测：按产品类型、适应症、应用和地区分類的全球分析
市场调查报告书
商品编码
1383450

2030 年奈米医学市场预测：按产品类型、适应症、应用和地区分類的全球分析

Nanomedicine Market Forecasts to 2030 - Global Analysis By Product Type (Nano Molecules, Nanoshells, Nanotubes, Nanodevices, and Nanoparticles), Modality, Indication, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球奈米药物市场规模将达2.359亿美元，预计2030年将达到4.96亿美元，预测期内年复合成长率为11.2%。

市面上有大量用于特定药物应用的奈米级材料，包括奈米颗粒、奈米载体和奈米管。奈米医学用于许多医疗应用，包括药物传输、影像、诊断、再生医学、癌症治疗和标靶治疗。尤其是奈米颗粒，可望将药物输送到体内的精确位置、减少副作用并提高治疗效率。

根据2021年7月发表的题为「医学和癌症奈米材料开发的最新进展」的研究论文，工程奈米材料和奈米平台正在开发中。

人们对标靶药物输送的兴趣日益浓厚

标靶药物输送使药物化合物（例如化疗）能够精确地输送到特定的疾病部位，例如癌细胞。透过这样做，我们可以提供更有效的药物来治疗患者，同时降低健康组织的风险。患者通常会受益于更好的治疗结果和更少的副作用。由于药物集中给药到所需位置，标靶给药可以用较低的药物剂量达到所需的治疗效果。这不仅可以最大限度地降低治疗成本，还可以减少副作用的机会。标靶药物传递可以提高患者对治疗的依从性，减少副作用并提高治疗效果，从而改善患者的整体预后。

安全问题

由于安全问题，患者可能对奈米医学产品缺乏信心并延迟获得这些治疗方法。儘管使用奈米医学治疗方法或参与临床试验有潜在的好处，但患者可能不愿意这样做。出于安全考虑，包括医生和医院在内的医疗保健提供者可能对提案或使用奈米医学治疗犹豫不决。因此，这些治疗方法的临床推广可能会被推迟，可能会阻碍市场成长。

奈米科技的进步

奈米技术的不断突破正在催生具有客製化特性的新型奈米材料。这些材料可以设计成具有特定的性能，如尺寸、形状、表面化学和生物相容性，使其成为各种医疗应用的理想选择。奈米技术已经能够建构先进的药物传输系统，包括脂质体、胶束和奈米颗粒。此外，这些系统可用于以受控和有针对性的方式封装和释放药物，从而提高治疗效果并减少副作用。

严格的法规要求

由于严格的法规限制和冗长的核准程序，将奈米医学产品推向市场可能会大大延迟。延误可能会阻碍患者获得可能挽救生命和改善生命的药物。对于奈米医学领域的小型和新成立的公司来说，满足市场进入的法律和财务先决条件可能特别困难。这些公司可能承受着不成比例的法规障碍，这也限制了它们的竞争能力。法规核准不透明且耗时，这可能会阻止公司和研究人员投资奈米医学研究。这会抑制产业的创新。

COVID-19 的影响

大流行的紧迫性刺激了奈米医学领域的研究和开发。奈米技术极大地促进了诊断测试、抗病毒药物传输系统和疫苗接种平台的发展。这项快速行动展示瞭如何利用奈米医学来应对新出现的卫生紧急情况。 COVID-19 疫苗是使用涉及脂质奈米粒子的奈米医学技术开发和交付的。各种 COVID-19 疫苗中使用的信使 RNA (mRNA) 被封装在这些脂质奈米粒子中，确保稳定性和细胞的有效吸收。

奈米壳细分市场预计将在预测期内成为最大的细分市场

透过调整金属壳的尺寸和成分，奈米壳可以被设计为散射和吸收特定波长的光，这被认为可以为奈米壳片段提供有利的生长。这种特性被用于一种称为「光热治疗」的方法。这种方法选择性地在癌细胞内积聚奈米壳，奈米壳响应近红外线光而产生热量，对细胞造成局部热损伤。这种方法提供了一种侵入性较小的去除癌细胞的方法。此外，奈米壳也用于医学成像。奈米壳在光学同调断层扫瞄和光声成像等成像模式中用作造影显影剂，从而推动了市场的发展。

诊断影像预计在预测期内具有最高的年复合成长率

在奈米医学领域，诊断成像至关重要，因为它提供了有关身体内部结构和活动的非侵入性且极其详细的视觉资讯。诊断成像受益于奈米技术的应用，提高了灵敏度、准确性以及针对特定疾病表现的能力。奈米技术的进步有利于分子成像技术，例如单光子发射电脑断层扫描（SPECT）和正子断层扫描（PET）。

比最大的地区

北美正在经历致命疾病数量的增加、奈米医学市场的蓬勃发展、最先进的医疗设施和合格医务人员的可用性、涉及知名人士的研发计划的增加以及政府支出的增加在医疗保健领域，预计将在预测期内占据最大的市场占有率。此外，该国正在进行大量基于奈米技术的药物和诊断的研发计划，这可能会促进市场扩张。例如，2020 年 1 月，史丹佛大学的科学家开发了一种涂有奈米颗粒的药物，可以透过减少小鼠动脉中形成的斑块数量来预防小鼠动脉粥状硬化的发展，而且没有任何副作用。我们开发了一种新药。

复合年复合成长率最高的地区：

由于公众对奈米科学和奈米技术相关共识会议的兴趣不断增加，以及对奈米医学的认识不断提高，预计亚太地区在预测期内将呈现最高的年复合成长率。例如，第九届国际奈米科学与技术会议（ChinaNANO 2022）于2022年8月在中国北京举行。会议的目的是共用科学发现、特定产业的进展、技术创新以及新的机会和挑战。此外，部门的开拓、新兴市场改革的兴起、奈米医学领域的技术进步以及医疗基础设施的改善是中国和日本预计在亚太市场实现高年复合成长率的主要原因。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球奈米医学市场：依产品类型

  • 奈米分子
  • 奈米壳
  • 奈米管
  • 奈米装置
  • 奈米颗粒
    • 金属和金属氧化物奈米颗粒
    • 树枝状聚合物
    • 水凝胶奈米粒子
    • 无机奈米粒子
    • 脂质体
    • 聚合物和聚合物药物缀合物

第6章全球奈米医学市场：依适应症分类

  • 感染疾病
  • 心血管疾病
  • 肿瘤性疾病
  • 整形外科疾病
  • 神经系统疾病
  • 泌尿系统疾病
  • 眼科疾病
  • 其他适应症

第7章全球奈米医学市场：依应用分类

  • 诊断影像
  • 再生医学
  • 药物输送
  • 疫苗
  • 植入
  • 其他用途

第8章全球奈米医学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Abbott
  • Sanofi SA
  • Pfizer Inc.
  • GE Healthcare
  • CombiMatrix Corporation
  • Johnson & Johnson Services Inc.
  • Luminex Corporation
  • Merck & Company Inc.
  • Nanosphere Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • DiaSorin SpA
  • Invitae Corporation
  • Mallinckrodt plc
  • Leadient BioSciences Inc.
  • Teva Pharmaceuticals Ltd.
  • Nanospectra Biosciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Ablynx
  • CytImmune Sciences
Product Code: SMRC24298

According to Stratistics MRC, the Global Nanomedicine Market is accounted for $235.9 million in 2023 and is expected to reach $496.0 million by 2030 growing at a CAGR of 11.2% during the forecast period. A vast array of nanoscale materials, including nanoparticles, nanocarriers, and nanotubes, that are intended for particular medicinal uses are available on the market. Numerous medical applications, such as medication delivery, imaging, diagnostics, regenerative medicine, cancer therapy, and targeted therapy, have made use of nanomedicine. Particularly nanoparticles have demonstrated promise in delivering medications to precise parts of the body, lowering side effects, and enhancing therapeutic efficiency.

According to a research article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer", published in July 2021, a wide range of engineered nanomaterials and nanoplatforms with different shapes, sizes, and compositions has been developed for various biomedical applications.

Market Dynamics:

Driver:

Growing interest on targeted drug delivery

With targeted medication delivery, medicinal compounds (such chemotherapy treatments) may be precisely delivered to certain disease locations, like cancer cells. By doing this, medications become more effective in treating patients while posing less of a risk to healthy tissues. Patients frequently benefit from this in terms of better treatment results and fewer side effects. Because the medication is concentrated at the intended place, targeted drug delivery can produce the intended therapeutic effect at lower drug dosages. This minimizes the expense of therapy as well as the chance of adverse consequences. Targeted medication delivery can improve patient compliance with therapy, which improves overall patient outcomes, by reducing side effects and improving treatment effectiveness.

Restraint:

Safety concerns

Patients may get less confident in nanomedicine products due to safety concerns, which may cause them to delay utilizing these treatments. Even if using nanomedicine therapies or taking part in clinical trials may have potential advantages, patients may be reluctant to do so. Because of safety concerns, healthcare providers including doctors and hospitals may be hesitant to propose or use nanomedicine therapy. As a result, these therapies may be adopted into clinical practice more slowly thus hampering the market growth.

Opportunity:

Increasing advancements in nanotechnology

Novel nanomaterials with customized characteristics have been created as a result of on-going breakthroughs in nanotechnology. These materials are ideal for a range of medical applications because they may be engineered to have certain properties including size, shape, surface chemistry, and biocompatibility. The creation of sophisticated medication delivery systems including liposomes, micelles, and nanoparticles has been made possible by nanotechnology. Moreover, the efficacy of therapies can be increased and adverse effects can be decreased by using these systems to encapsulate and release medications in a controlled and targeted way.

Threat:

Stringent regulatory requirements

The release of goods utilizing nanomedicines into the market might be seriously delayed by onerous regulatory restrictions and protracted approval procedures. Access for patients to potentially life-saving or life-improving medicines may be hampered by delays. It may be especially difficult for small and newly established businesses in the field of nanomedicine to fulfil the legal and financial prerequisites for entering the market. These businesses may be disproportionately burdened by regulatory obstacles, which also restrict their capacity to compete. Because regulatory approval is unclear and takes time, companies and researchers may be deterred from investing in nanomedicine research. This may inhibit industry innovation.

COVID-19 Impact

The pandemic's urgency spurred study and development in the field of nanomedicine. The development of diagnostic testing, antiviral medication delivery systems, and vaccination platforms were significantly aided by nanotechnology. This prompt action showed how nanomedicine may be used to meet new health emergencies. COVID-19 vaccines were developed and delivered using nanomedicine technology, including lipid nanoparticles. The messenger RNA (mRNA) utilized in various COVID-19 vaccines is encapsulated in these lipid nanoparticles, which guarantees their stability and effective uptake by cells.

The nanoshells segment is expected to be the largest during the forecast period

The nanoshells segment is estimated to have a lucrative growth, as these may be engineered to scatter and absorb light at particular wavelengths by adjusting the metallic shell's size and composition. This characteristic is utilized in a method known as "photothermal therapy." This approach involves the selective accumulation of nanoshells within cancer cells, which heat up in response to near-infrared light and inflict localized thermal damage on the cells. This method provides a less intrusive means of eliminating cancer cells. Moreover, nanoshells have been used to medical imaging. They can be used as contrast agents in imaging modalities such as optical coherence tomography and photoacoustic imaging which boosts the market.

The diagnostic imaging segment is expected to have the highest CAGR during the forecast period

The diagnostic imaging segment is anticipated to witness the highest CAGR growth during the forecast period, as in the field of nanomedicine, diagnostic imaging is essential because it offers non-invasive, incredibly detailed visual information on the interior structures and activities of the body. Diagnostic imaging has benefited from the application of nanotechnology, which has increased sensitivity, accuracy, and the capacity to target certain disease signs. Advances in nanotechnology have been beneficial for molecular imaging techniques like single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing an increase in the number of deadly illnesses, a spike in the market for nanomedicines, the availability of cutting-edge medical facilities staffed by qualified medical personnel, an increase in the number of R&D projects involving prominent figures, and an increase in government spending in the healthcare sector. Additionally, the nation is conducting a number of R&D projects on medications and diagnostics based on nanotechnology, which might propel market expansion. For example, in January 2020, scientists at Stanford University created a medication coated with nanoparticles that prevents mice from developing atherosclerosis by lowering the amount of plaque that accumulates in their arteries without having any negative side effects.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to public's growing interest in consensus conferences related to nanoscience and nanotechnology as well as the growing awareness of nanomedicine. For example, ChinaNANO 2022, the 9th International Conference on Nanoscience and Technology, was held in Beijing, China in August 2022. The purpose of the conference is to share scientific discoveries, advances in certain industries, technological innovations, and novel opportunities and challenges. Furthermore, the development of the R&D sector, the rise in healthcare reforms, the advancement of technology in the field of nanomedicines, and improvements in healthcare infrastructure are the main reasons why China and Japan are predicted to grow at a high compound annual growth rate (CAGR) in the Asia-Pacific market.

Key players in the market

Some of the key players profiled in the Nanomedicine Market include: Abbott, Sanofi SA, Pfizer Inc., GE Healthcare, CombiMatrix Corporation, Johnson & Johnson Services Inc., Luminex Corporation, Merck & Company Inc., Nanosphere Inc. , Celgene Corporation, Bristol-Myers Squibb Company, DiaSo, Invitae Corporation, Mallinckrodt plc, Leadient BioSciences Inc., Teva Pharmaceuticals Ltd., Nanospectra Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Ablynx and CytImmune Sciences

Key Developments:

In November 2023, Abbott has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.

In October 2023, Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment. Collaboration supports Sanofi's immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Product Types Covered:

  • Nano Molecules
  • Nanoshells
  • Nanotubes
  • Nanodevices
  • Nanoparticles

Indications Covered:

  • Infectious Diseases
  • Cardiovascular Diseases
  • Oncological Diseases
  • Orthopedic Diseases
  • Neurological Disorders
  • Urological Disorders
  • Ophthalmological Diseases
  • Other Indications

Applications Covered:

  • Diagnostic Imaging
  • Regenerative Medicine
  • Drug Delivery
  • Vaccines
  • Implants
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanomedicine Market, By Product Type

  • 5.1 Introduction
  • 5.2 Nano Molecules
  • 5.3 Nanoshells
  • 5.4 Nanotubes
  • 5.5 Nanodevices
  • 5.6 Nanoparticles
    • 5.6.1 Metal & Metal Oxide Nanoparticles
    • 5.6.2 Dendrimers
    • 5.6.3 Hydrogel Nanoparticles
    • 5.6.4 Inorganic nanoparticles
    • 5.6.5 Liposomes
    • 5.6.6 Polymer and Polymer Drug Conjugates

6 Global Nanomedicine Market, By Indication

  • 6.1 Introduction
  • 6.2 Infectious Diseases
  • 6.3 Cardiovascular Diseases
  • 6.4 Oncological Diseases
  • 6.5 Orthopedic Diseases
  • 6.6 Neurological Disorders
  • 6.7 Urological Disorders
  • 6.8 Ophthalmological Diseases
  • 6.9 Other Indications

7 Global Nanomedicine Market, By Application

  • 7.1 Introduction
  • 7.2 Diagnostic Imaging
  • 7.3 Regenerative Medicine
  • 7.4 Drug Delivery
  • 7.5 Vaccines
  • 7.6 Implants
  • 7.7 Other Applications

8 Global Nanomedicine Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott
  • 10.2 Sanofi SA
  • 10.3 Pfizer Inc.
  • 10.4 GE Healthcare
  • 10.5 CombiMatrix Corporation
  • 10.6 Johnson & Johnson Services Inc.
  • 10.7 Luminex Corporation
  • 10.8 Merck & Company Inc.
  • 10.9 Nanosphere Inc.
  • 10.10 Celgene Corporation
  • 10.11 Bristol-Myers Squibb Company
  • 10.12 DiaSorin S.p.A.
  • 10.13 Invitae Corporation
  • 10.14 Mallinckrodt plc
  • 10.15 Leadient BioSciences Inc.
  • 10.16 Teva Pharmaceuticals Ltd.
  • 10.17 Nanospectra Biosciences, Inc.
  • 10.18 Arrowhead Pharmaceuticals, Inc.
  • 10.19 Ablynx
  • 10.20 CytImmune Sciences

List of Tables

  • Table 1 Global Nanomedicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nanomedicine Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Nanomedicine Market Outlook, By Nano Molecules (2021-2030) ($MN)
  • Table 4 Global Nanomedicine Market Outlook, By Nanoshells (2021-2030) ($MN)
  • Table 5 Global Nanomedicine Market Outlook, By Nanotubes (2021-2030) ($MN)
  • Table 6 Global Nanomedicine Market Outlook, By Nanodevices (2021-2030) ($MN)
  • Table 7 Global Nanomedicine Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 8 Global Nanomedicine Market Outlook, By Metal & Metal Oxide Nanoparticles (2021-2030) ($MN)
  • Table 9 Global Nanomedicine Market Outlook, By Dendrimers (2021-2030) ($MN)
  • Table 10 Global Nanomedicine Market Outlook, By Hydrogel Nanoparticles (2021-2030) ($MN)
  • Table 11 Global Nanomedicine Market Outlook, By Inorganic nanoparticles (2021-2030) ($MN)
  • Table 12 Global Nanomedicine Market Outlook, By Liposomes (2021-2030) ($MN)
  • Table 13 Global Nanomedicine Market Outlook, By Polymer and Polymer Drug Conjugates (2021-2030) ($MN)
  • Table 14 Global Nanomedicine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 15 Global Nanomedicine Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 16 Global Nanomedicine Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 17 Global Nanomedicine Market Outlook, By Oncological Diseases (2021-2030) ($MN)
  • Table 18 Global Nanomedicine Market Outlook, By Orthopedic Diseases (2021-2030) ($MN)
  • Table 19 Global Nanomedicine Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 20 Global Nanomedicine Market Outlook, By Urological Disorders (2021-2030) ($MN)
  • Table 21 Global Nanomedicine Market Outlook, By Ophthalmological Diseases (2021-2030) ($MN)
  • Table 22 Global Nanomedicine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 23 Global Nanomedicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Nanomedicine Market Outlook, By Diagnostic Imaging (2021-2030) ($MN)
  • Table 25 Global Nanomedicine Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 26 Global Nanomedicine Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 27 Global Nanomedicine Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 28 Global Nanomedicine Market Outlook, By Implants (2021-2030) ($MN)
  • Table 29 Global Nanomedicine Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.